Abbvie Exec Says Will Evaluate Subcutaneous Skyrizi In Induction Phase For Ulcerative Colitis; See Further EPS Expansion Beyond The High Single-Digit Compound Annual Revenue Growth Forecast From 2024 Through 2029
AbbVie, Inc. -0.84%
AbbVie, Inc. ABBV | 206.77 | -0.84% |
https://event.summitcast.com/view/9z5g2VrV6e6rbCqQgDRoHA/Y7w6ak8fVSTKmxSCNHGfCs
